← Back to Search

Monoclonal Antibodies

Ramucirumab + Atezolizumab + N-803 for Non-Small Cell Lung Cancer (RAN Trial)

Phase 2
Waitlist Available
Led By Daniel Morgensztern, M.D.
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through completion of follow-up (estimated to be 30 months)
Awards & highlights

Summary

This trial will test if adding ramucirumab and N-803 to atezolizumab will help patients with lung cancer.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Non-Small Cell Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through completion of follow-up (estimated to be 30 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and through completion of follow-up (estimated to be 30 months) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Objective response rate (ORR)
Secondary study objectives
Clinical benefit rate (CBR)
Immune best overall response (iBOR)
Immune progression-free survival (iPFS)
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Ramucirumab + Atezolizumab + N-803Experimental Treatment3 Interventions
-Ramucirumab intravenously (IV) on Day 1, atezolizumab IV on Day 1, and N-803 subcutaneous (SC) on Day 1 of each cycle. Cycles are 21 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ramucirumab
2017
Completed Phase 3
~5050
Atezolizumab
2017
Completed Phase 3
~5860
N-803
2021
Completed Phase 2
~30

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
1,970 Previous Clinical Trials
2,313,829 Total Patients Enrolled
Eli Lilly and CompanyIndustry Sponsor
2,639 Previous Clinical Trials
3,222,718 Total Patients Enrolled
ImmunityBio, Inc.Industry Sponsor
65 Previous Clinical Trials
4,970 Total Patients Enrolled
~0 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top